• shareshare
  • link
  • cite
  • add
auto_awesome_motion View all 2 versions
Publication . Article . 2020


Andrey Kaprin; Elena V. Gameeva; Alexander A. Polyakov; Anna L. Kornietskaya; Natalia A. Rubtsova; Alexander A. Fedenko;
Open Access   Russian  
Published: 06 Jul 2020 Journal: Sibirskij Onkologičeskij Žurnal, volume 19, issue 3, pages 5-22 (issn: 1814-4861, eissn: 2312-3168, Copyright policy )
Publisher: Tomsk National Research Medical Center of the Russian Academy of Sciences
Detailed, systematic review of the world literature data, including all aspects that reflect the impact of the COVID-19 pandemic on the oncological practice was conducted. The information sources were taken from Pubmed, MedLine, Scopus, Web of Science, and RSCI systems. The data from retrospective and prospective clinical trials have been analyzed. This review presents current data on the impact of COVID-19 on cancer patients, mortality and prognosis of cancer patients infected with COVID-19, treatment options for COVID-19, as well as the case report of the cancer patient with rare atypical COVID-19 course of disease. To date, the groups of increased risk of being infected with a new coronavirus have been identified. These groups include cancer patients. Despite the pandemic, treatment of cancer patients must be continued, since the presence of a tumor process does not allow the therapy to be delayed. The world cancer community is actively continuing to develop recommendations for optimal management of cancer patients in the context of the pandemic. The most relevant of them are described in this article.
Subjects by Vocabulary

Microsoft Academic Graph classification: Intensive care medicine medicine.medical_specialty medicine Clinical trial Context (language use) Pandemic Scopus Optimal management business.industry business Cancer medicine.disease MEDLINE Coronavirus disease 2019 (COVID-19)


covid-19, sars-cov-2, pandemic, oncology, drug treatment of tumors, oncohematology, solid tumors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cancer Research